The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,050.00
Bid: 12,038.00
Ask: 12,040.00
Change: 0.00 (0.00%)
Spread: 2.00 (0.017%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 12,050.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE 1-AstraZeneca reaches vaccine shipping milestone as EU sues again

Mon, 10th May 2021 17:12

(adds legal case, duration of contract)

By Francesco Guarascio

BRUSSELS, May 10 (Reuters) - AstraZeneca Plc has
delivered 50 million doses of its COVID-19 vaccine to European
Union countries, according to EU supply data, a milestone the
company had originally been expected to hit in January.

The volumes delivered make up just one-sixth of total
commitments so far, and the European Commission is set to launch
on Tuesday a second legal case against AstraZeneca over delayed
deliveries, a spokesman for the EU executive said on Monday.

Repeated cuts to supplies, which contributed to delays in
the EU's vaccination drive, pushed the EU Commission to sue the
Anglo-Swedish drugmaker in late April in a bid to get more doses
by mid-year.

On Tuesday, it will launch a new case on the merits of the
issue, which an official familiar with the proceedings said was
mostly procedural but would allow the EU to seek potential
financial penalties.

AstraZeneca had shipped nearly 50 million doses as of May 7,
an EU official told Reuters on Monday, citing the latest EU
internal figures on vaccine supplies.

In mid-March, the company had pledged to deliver 50.2
million doses to the EU by the end of April, an AstraZeneca
document seen by Reuters showed.

But AstraZeneca had shipped only 47.6 million doses by April
30, a spokesman for the company said, adding that other doses
were sent over the first weekend of May and in the following
days, "following requests to not ship to a few countries that
had public holidays during this period".

Immediately after the EU sued the company, AstraZeneca
issued a statement on April 26 saying it would deliver "almost
50 million doses to European countries by the end of April".

Under its contract with the EU, the company had committed to
its "best reasonable efforts" to deliver 300 million doses by
the end of June, of which 70 million were supposed to be
delivered by the end of January.

Citing production problems and export restrictions,
AstraZeneca in March said it would deliver to the EU only 100
million doses by the end of June. It delivered 30 million in
total by the end of March.

The vaccine was approved for use in the EU in late January,
but the EU Commission has said AstraZeneca should have applied
earlier.

The EU wants to receive as many doses as possible of the 300
million contracted, but in a further sign of its lost confidence
in AstraZeneca, it has already decided not to take up an option
within the contract for 100 million additional doses.

On Sunday, EU industry commissioner Thierry Breton said the
commission was also not planning to negotiate a new contract
with the firm.

(Reporting by Francesco Guarascio;
Editing by Bill Berkrot and Bernadette Baum)

More News
16 Jan 2024 08:15

UBS downgrades AstraZeneca to 'sell'

(Sharecast News) - UBS has downgraded AstraZeneca and upgraded rival GSK as part of its latest review of the European pharmaceutical sector.

Read more
9 Jan 2024 10:50

Novartis in advanced talks to buy Cytokinetics- source

Jan 9 (Reuters) - Swiss drugmaker Novartis is in the lead to acquire Cytokinetics in a deal that could value the drug developer at well over $10 billion, a source familiar with the matter said on Monday.

Read more
8 Jan 2024 14:08

Late M&A bonanza stokes healthcare dealmakers ahead of JPMorgan conference

NEW YORK, Jan 5 (Reuters) - Healthcare dealmakers are making their way to San Francisco for a major industry conference, optimistic that more deals are in the offing after a wave of biotech company takeovers at the end of last year.

Read more
6 Jan 2024 17:44

Late M&A bonanza stokes healthcare dealmakers ahead of JPMorgan conference

NEW YORK, Jan 5 (Reuters) - Healthcare dealmakers are making their way to San Francisco for a major industry conference, optimistic that more deals are in the offing after a wave of biotech company takeovers at the end of last year.

Read more
5 Jan 2024 12:00

Late M&A bonanza stokes healthcare dealmakers ahead of JPMorgan conference

NEW YORK, Jan 5 (Reuters) - Healthcare dealmakers are making their way to San Francisco for a major industry conference, optimistic that more deals are in the offing after a wave of biotech company takeovers at the end of last year.

Read more
3 Jan 2024 17:48

London close: Stocks fall amid rising geopolitical concerns

(Sharecast News) - London stocks closed lower on Wednesday - the 40th anniversary of the FTSE 100's launch - as sentiment remained cautious due to increasing tensions in the Middle East.

Read more
3 Jan 2024 16:52

LONDON MARKET CLOSE: Stocks down ahead of US Fed minutes

(Alliance News) - Stock prices in London closed lower on Wednesday, as investors nervously look ahead to the latest US Federal Reserve meeting minutes.

Read more
3 Jan 2024 11:07

Jefferies upgrades GSK to 'buy', cuts AstraZeneca to 'hold'

(Sharecast News) - Jefferies has upgraded its rating on GlaxoSmithKline to 'buy' and cut AstraZeneca to 'hold' as part of its review of the European pharma sector.

Read more
3 Jan 2024 10:16

IN BRIEF: Nuformix narrows annual loss as develops drug assets

Nuformix PLC - London-based developer of treatments for fibrosis and oncology via drug repurposing - Pretax loss narrows to GBP927,972 in 18 months that ended September 30 from GBP1.3 million in the 12 months that ended March 31, 2022, following its change of financial year-end. Has no meaningful revenue in either period, so reduced loss is due to lower administrative expenses.

Read more
3 Jan 2024 10:12

AIM WINNERS & LOSERS: C4X gets Astra payment; Getech wins eight deals

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Wednesday.

Read more
3 Jan 2024 09:23

LONDON BROKER RATINGS: GSK raised to 'buy'; AstraZeneca cut to 'hold'

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

Read more
3 Jan 2024 08:58

LONDON MARKET OPEN: Stocks mixed pre-Fed minutes, amid Asia losses

(Alliance News) - Stock prices in London opened mixed on Wednesday, ahead of US Federal Reserve meeting minutes and manufacturing PMI data for the US in the evening and afternoon respectively.

Read more
3 Jan 2024 08:04

C4X receives USD11 million from AstraZeneca following NRF2 trials

(Alliance News) - C4X Discovery Holdings PLC on Wednesday said it has received payment from AstraZeneca PLC following trials of the C4X respiratory disease therapy treatment.

Read more
3 Jan 2024 07:54

LONDON BRIEFING: Stocks to open flat pre-Fed minutes, jobs data

(Alliance News) - The FTSE 100 is expected to open flat on Wednesday, as London's flagship index celebrates its 40th anniversary, after mostly downbeat trading in Asia and a tech sell-off in New York.

Read more
2 Jan 2024 17:05

British equities slip on higher yields, financials drag

FTSE 100 down 0.2%, FTSE 250 off 0.9%

*

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.